scholarly journals Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases

Author(s):  
Emrullah Korkmaz ◽  
Stephen C. Balmert ◽  
Cara Donahue Carey ◽  
Geza Erdos ◽  
Louis D. Falo
2016 ◽  
Vol 4 (11) ◽  
pp. 1535-1553 ◽  
Author(s):  
Arti Vashist ◽  
Ajeet Kaushik ◽  
Atul Vashist ◽  
Rahul Dev Jayant ◽  
Asahi Tomitaka ◽  
...  

Hydrogel based drug delivery systems owe excellent potential as targeted drug delivery systems for the delivery of therapeutic agents and diagnostics for major infectious diseases.


2020 ◽  
Vol 21 ◽  
Author(s):  
Masood Alam Khan

Abstract:: Tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg), acts as an immunopotentiating molecule with its ability to bind and activate many immune cells, including macrophages or monocytes, neutrophils and dendritic cells. The specific targeting activity of tuftsin has been further increased by its palmitoylation followed by its incorporation into the lipid bilayer of liposomes. Tuftsin-bearing liposomes (Tuft-liposomes) possess several characteristics that enable them to act as a potential drug and vaccine carriers. Tuft-liposomes-loaded anti-microbial drugs have been shown to be highly effective against many infectious diseases, including tuberculosis, leishmaniasis, malaria, candidiasis, cryptococosis. Moreover, Tuft-liposomes also increased the activity of anticancer drug etoposide against fibrosarcoma in mice. Tuft-liposomes showed the immune-potentiating effect and rejuvenated the immune cells in the leukopenic mice. In addition, antigens encapsulated in Tuftsin-bearing liposomes demonstrated greater immunogenicity by increasing the T cell proliferation and antibody secretion. Keep-ing into consideration of their specific targeting and immunopotentiating effects, Tuft-liposomes may potentially be used as promising drug and vaccine delivery systems.


2009 ◽  
Vol 7 (suppl_1) ◽  
Author(s):  
Wiebke Ulbrich ◽  
Alf Lamprecht

Limitations in therapy induced by adverse effects due to unselective drug availability and therefore the use of potentially too high doses are a common problem. One prominent example for this dilemma are inflammatory diseases. Colloidal carriers allow one to improve delivery of drugs to the site of action and appear promising to overcome this general therapeutic drawback. Specific uptake of nanoparticles by immune-related cells in inflamed barriers offers selective drug targeting to the inflamed tissue. Here we focus on nanocarrier-based drug delivery strategies for the treatment of common inflammatory disorders like rheumatoid arthritis, multiple sclerosis, uveitis or inflammatory bowel disease.


2014 ◽  
Vol 4 (3) ◽  
pp. 193-201 ◽  
Author(s):  
Xiaoli Wei ◽  
Xishan Chen ◽  
Man Ying ◽  
Weiyue Lu

Sign in / Sign up

Export Citation Format

Share Document